The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
The FDA grants tazemetostat (EPZ-6438) Fast Track Designation for treatment of relapsed/refractory Follicular Lymphoma
On 25th April 2017, tazemetostat (EPZ-6438), an orally administered, first-in-class, small molecule EZH2 inhibitor, was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with R/R FL regardless of EZH2 mutation.
This is the second Fast Track Designation given to Epizyme’s tazemetostat; in January 2017 the Lymphoma Hub reported on the first Fast Track status for R/R DLBCL with EZH2-activating mutations.
Tazemetostat is being assessed as a single-agent and in combination in numerous clinical trials. Trials currently recruiting include a phase I trial of tazemetostat combined with atezolizumab in patients with R/R DLBCL (NCT02220842) and a phase I/II trial of tazemetostat combined with R-CHOP in older patients (60–80 years old) with newly diagnosed DLBCL (NCT02889523).
Moreover, Epizyme has announced that it will present interim effectiveness and safety data from 5 cohorts in an ongoing phase II trial in R/R FL and DLBCL at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland, in June. Data from a biomarker study of tazemetostat in NHL patients will also be presented during the conference in a poster session.
References